Headquartered in Indianapolis, IN·Fiscal year ends December·NYSE: LLY·lilly.com
About Eli Lilly
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and sells medicines across diabetes, obesity, oncology, immunology and neuroscience.
Its revenue is concentrated in incretin therapies based on tirzepatide: Mounjaro for type 2 diabetes, now also FDA-approved to reduce cardiovascular risk, and Zepbound for obesity. Lilly's oral GLP-1 Foundayo (orforglipron) is in global launch.
Other Key Products include:
- Jaypirca, a non-covalent BTK inhibitor for CLL/SLL
- Inluriyo (imlunestrant) for ESR1-mutated breast cancer
- Ebglyss (lebrikizumab) for atopic dermatitis
- Omvoh (mirikizumab) for ulcerative colitis and Crohn's disease
- Kisunla for Alzheimer's disease
The broader portfolio includes Verzenio, Taltz, Olumiant, the newly approved once-weekly basal insulin Onswik, and Jardiance through a collaboration with Boehringer Ingelheim.
Lilly's pipeline spans retatrutide (a triple agonist), the eloralintide/tirzepatide combination EloraTZP, olomorasib and a next-generation FRα-targeting ADC.
The company is expanding through acquisitions, including AtaiBeckley in mental health and Merida Biosciences in autoimmune and allergic disease. It is also building out U.S. manufacturing, with ten new U.S. sites announced since 2020, including Houston and Richmond.
Revenue is generated in the U.S. and internationally, with fast growth outside the U.S. driven by Mounjaro, including in China following NRDL inclusion. Updated
Lilly is absorbing lower GLP-1 pricing, with 53% more patients on its drugs funding a push into gene editing and oncology.
Eli Lilly cut its prices 15% and still sold $24.4B in three months, up 39%.
How?
53% more people are taking its drugs.
Its next weight loss shot took off about 28% of patients' body weight in trials.
The weight loss money is now paying for gene editing, cancer drugs and cell https://t.co/eaqcVLBSEm
[Quoted @ThierryBorgeat]: CEO of Eli Lilly $LLY
The biggest beneficiary of AI is Biotech.
The case:
https://t.co/V2nfeWzPehhttps://t.co/iyKmslKzcvhttps://t.co/3gvq5zfzdP
51 stocks printed fresh 52-week highs this week, and the leadership is energy plus big biotech: Cheniere cleared its prior peak by 11.7%, with Regeneron, Eli Lilly and Gilead all stretching more than 8% past theirs.
A 4.05% intraday gain on a $1.2 trillion company is roughly $50 billion in market value, and it follows this morning's Q3 2026 earnings beat. Moves this size are rare for a megacap this heavy, so keep an eye on whether it holds into the close.
A 32-point gap separates the best and worst names in a 381-stock universe today: ServiceNow and Fortinet both shed roughly 24% while Eli Lilly leads the upside at 7.72%. Positioning set for a quiet session is already wrong.
Lilly lifted full-year revenue guidance to $91 billion to $92 billion, up from $85 billion to $87 billion, after tirzepatide volume rose 53% worldwide. EPS and revenue both beat expectations despite acquired IPR&D charges from the AtaiBeckley and Curevo deals landing in the quarter.
New 52-week high$1,283.66+0.3% vs prior high · 2026-08-19
Eli Lilly just cleared its August 19 peak with a $1,283.66 close, a new 52-week high for the $1.1 trillion drugmaker. The stock has climbed roughly 60% from last October's $803 level, and two months of chop are now resolved to the upside.
Defense and big pharma own the top of the board at the open, led by Northrop Grumman up 5.36%, with Eli Lilly, Bristol-Myers Squibb and Merck also higher. The pain is concentrated in crypto miners and optics names, where IREN leads the decline.
Diversification pitch: Korean memory selling in SK Hynix and Samsung is bleeding into US data center names
Schwab called a buy near $94, under 15x this year's earnings, after AI displacement fears knocked it from $114
Chevron preferred over Exxon on a swap; Home Depot held as the most rate-levered name he knows
Trim half of Oracle after the run; Microsoft left alone into earnings on Azure strength
Cramer is pulling money toward consumer staples, retailers and oils while the data center complex cracks, and he is framing Schwab's selloff on AI-agent worries as a repeat of the 2023 banking scare that proved a buying opportunity. For anyone concentrated in AI hardware, the Oracle half-sell is the clearest sell discipline he offered all episode.
A 3.32% intraday gain to $1,214.81 adds roughly $36 billion in market value, the kind of single-session swing a $1.1 trillion company rarely posts. Keep an eye on whether it holds into the close.
Mounjaro and Zepbound just handed Lilly a blowout quarter, but falling realized drug prices and one-time revenue boosts that won't repeat raise real questions about whether the rally holds from here.
Mounjaro and Zepbound built Lilly into a trillion-dollar company, but a surge in oncology, immunology, and neuroscience revenue hints that the real growth story is just getting started.
Two health care ETFs track the same sector but own very different slices of it, and for retirees building a portfolio, that gap in biotech exposure and concentration could matter more than…
Merck (NYSE:MRK | MRK Price Prediction) is the second big drugmaker to reward investors with an earnings beat and a raised profit outlook. However, Merck’s steady, Keytruda-anchored growth tells a very different…
Eli Lilly (NYSE:LLY | LLY Price Prediction) just extended its lead in obesity drugs, and its newer cancer, immunology and neuroscience products are starting to matter, while the rest of the glucagon-like…
Employers are quietly reconsidering who foots the bill for GLP-1 weight-loss drugs, and the fallout hits Eli Lilly and Novo Nordisk very differently heading into earnings week.
Eli Lilly's EPS estimate collapsed by a third in just 30 days, Merck faces a comparison it cannot repeat, and Gilead is burning through cash fast. Three pharma giants report Thursday, and…
Eli Lilly (NYSE:LLY | LLY Price Prediction) reports third-quarter results on October 29. It brings a streak of 5 consecutive EPS beats and a stock that has run hard into the report.…
Heineken just told British pub owners that a blockbuster class of drugs threatens the very ritual of buying a round, and its own financial data makes the warning harder to dismiss than…
A UBS portfolio manager sees three technology waves pushing stocks far beyond Wall Street's consensus, but his bullish case runs straight through two more Fed rate hikes that most investors are not…
A European regulatory endorsement for an oral obesity pill is lifting Eli Lilly (NYSE:LLY | LLY Price Prediction) stock ahead of the rest of the drug group. Eli Lilly stock is up…
Eli Lilly just posted 47.7% revenue growth and its weight-loss drugs are reshaping global healthcare, but whether that momentum turns a four-year investment into a windfall or a disappointment depends on factors…
Eli Lilly just crushed earnings again and sits within striking distance of its all-time high, but a looming price war with Novo Nordisk and a dangerously concentrated revenue base raise real questions…
Eli Lilly spent most of its 150-year history as a quiet insulin maker before a single drug reshuffled the entire obesity market and turned a modest stake into a fortune that left…
Johnson and Johnson crushed earnings, raised guidance, and still watched its stock crater nearly 6% in a single session. Understanding what spooked investors reveals whether Tuesday's selloff is a trap or a…
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and sells medicines across diabetes, obesity, oncology, immunology and neuroscience.
What is the LLY stock price target?
24/7 Wall St.'s 12-month price target for LLY is $1,621.09, rated Buy. The Wall Street consensus target is $1,403.64. LLY price prediction →
